{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T04:32:22Z","timestamp":1792384342270,"version":"4.4.0"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.biopha.2026.119299","type":"journal-article","created":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T11:20:38Z","timestamp":1775388038000},"page":"119299","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise?"],"prefix":"10.1016","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-3659-4523","authenticated-orcid":false,"given":"Thoa T.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vu L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa L.","family":"Fishel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ba-Thong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Condello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119299_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41021-025-00326-y","article-title":"Cancer prevention: past challenges and future directions","volume":"47","author":"Seong","year":"2025","journal-title":"Genes Environ."},{"key":"10.1016\/j.biopha.2026.119299_bib2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1038\/s41392-024-01808-1","article-title":"Drug repurposing for cancer therapy","volume":"9","author":"Xia","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2026.118683","article-title":"Aptamers-based drug: A new paradigm for precise treatment","volume":"307","author":"Zhou","year":"2026","journal-title":"Eur. J. Med Chem."},{"key":"10.1016\/j.biopha.2026.119299_bib5","article-title":"Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers","volume":"34","author":"Mashayekhi","year":"2026","journal-title":"Mol. Ther. Oncol."},{"key":"10.1016\/j.biopha.2026.119299_bib6","article-title":"Aptamer-liposome targeted nanotherapeutics for cancer therapy: Bibliometric analysis, recent developments and future perspectives","volume":"36","author":"Gao","year":"2026","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biopha.2026.119299_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2025.115646","article-title":"From cell-SELEX to tissue-SELEX for targeted drug delivery and aptamer nanomedicine","volume":"224","author":"Wong","year":"2025","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2026.119299_bib8","first-page":"246","article-title":"Aptamer-Based Immunotheranostic Strategies","volume":"38","author":"Garcia Melian","year":"2023","journal-title":"Cancer Biother Radio."},{"key":"10.1016\/j.biopha.2026.119299_bib9","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1016\/j.ymthe.2021.06.010","article-title":"Aptamers: Cutting edge of cancer therapies","volume":"29","author":"Shigdar","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib10","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.biopha.2026.119299_bib11","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/355850a0","article-title":"Selection in vitro of single-stranded DNA molecules that fold into specific ligand-binding structures","volume":"355","author":"Ellington","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119299_bib12","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2026.119299_bib13","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nrd3141","article-title":"Aptamers as therapeutics","volume":"9","author":"Keefe","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119299_bib14","doi-asserted-by":"crossref","first-page":"43272","DOI":"10.1038\/srep43272","article-title":"Regulation of photosensitisation processes by an RNA aptamer","volume":"7","author":"Thoa","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119299_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10010009","article-title":"Current Advances in Aptamers for Cancer Diagnosis and Therapy","volume":"10","author":"Hori","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119299_bib16","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12935-024-03295-4","article-title":"Aptamers as an approach to targeted cancer therapy","volume":"24","author":"Mahmoudian","year":"2024","journal-title":"Cancer Cell Int"},{"key":"10.1016\/j.biopha.2026.119299_bib17","doi-asserted-by":"crossref","first-page":"32231","DOI":"10.1021\/acsomega.3c04345","article-title":"Recent Advancements of Aptamers in Cancer Therapy","volume":"8","author":"Venkatesan","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119299_bib18","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/mt.2013.300","article-title":"Inhibition of receptor signaling and of glioblastoma-derived tumor growth by a novel PDGFR\u03b2 aptamer","volume":"22","author":"Camorani","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib19","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.canlet.2012.11.032","article-title":"RNA aptamers targeting cancer stem cell marker CD133","volume":"330","author":"Shigdar","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119299_bib20","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.omtn.2017.08.006","article-title":"A CTLA-4 Antagonizing DNA Aptamer with Antitumor Effect","volume":"8","author":"Huang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119299_bib21","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/mt.2011.145","article-title":"Targeting 4-1BB costimulation to disseminated tumor lesions with bi-specific oligonucleotide aptamers","volume":"19","author":"Pastor","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib22","doi-asserted-by":"crossref","first-page":"44","DOI":"10.17116\/neiro20258906244","article-title":"[Aptamer-based conjugated molecules in experimental and clinical approaches to treatment of glioblastoma]","volume":"89","author":"Kobyakov","year":"2025","journal-title":"Zh Vopr. Neirokhir Im. N. N. Burd."},{"key":"10.1016\/j.biopha.2026.119299_bib23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrd1955","article-title":"Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease","volume":"5","author":"Ng","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119299_bib24","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/S0008-4182(05)80078-X","article-title":"Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration","volume":"40","author":"Ng","year":"2005","journal-title":"Can. J. Ophthalmol."},{"key":"10.1016\/j.biopha.2026.119299_bib25","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1080\/14656566.2023.2257604","article-title":"The complement system: a novel therapeutic target for age-related macular degeneration","volume":"24","author":"Shughoury","year":"2023","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.biopha.2026.119299_bib26","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1097\/MS9.0000000000002021","article-title":"Izervay (avacincaptad pegol): paving the way for vision preservation in geographic atrophy","volume":"86","author":"Shakeel","year":"2024","journal-title":"Ann. Med Surg. (Lond."},{"key":"10.1016\/j.biopha.2026.119299_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2025.101350","article-title":"The recent blooming of therapeutic aptamers","volume":"102","author":"Cesarini","year":"2025","journal-title":"Mol. Asp. Med"},{"key":"10.1016\/j.biopha.2026.119299_bib28","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41592-024-02487-0","article-title":"Accurate RNA 3D structure prediction using a language model-based deep learning approach","volume":"21","author":"Shen","year":"2024","journal-title":"Nat. Methods"},{"key":"10.1016\/j.biopha.2026.119299_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.124173","article-title":"Advances in aptamer-mediated targeted delivery system for cancer treatment","volume":"238","author":"He","year":"2023","journal-title":"Int J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119299_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13206-021-00016-1","article-title":"Sehoon Jeong Organ\u2011on\u2011a\u2011Chip: The Future of Therapeutic Aptamer Research?","volume":"7","author":"Thoa Thi Thanh Tran","year":"2021","journal-title":"BioChip J."},{"key":"10.1016\/j.biopha.2026.119299_bib31","article-title":"Analysis of aptamer discovery and technology","volume":"1","author":"Dunn","year":"2017","journal-title":"J. Nat. Rev. Chem."},{"key":"10.1016\/j.biopha.2026.119299_bib32","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.apsb.2023.01.017","article-title":"Recent progress of aptamer-drug conjugates in cancer therapy","volume":"13","author":"He","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.biopha.2026.119299_bib33","doi-asserted-by":"crossref","first-page":"5670","DOI":"10.1093\/nar\/gkl718","article-title":"Codeine-binding RNA aptamers and rapid determination of their binding constants using a direct coupling surface plasmon resonance assay","volume":"34","author":"Win","year":"2006","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.biopha.2026.119299_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2026.150299","article-title":"Structure-affinity balance of anti-cardiac troponin I aptamer: Effects of sequence truncation","volume":"341","author":"Krasitskaya","year":"2026","journal-title":"Int J. Biol. Macromol."},{"key":"10.1016\/j.biopha.2026.119299_bib35","doi-asserted-by":"crossref","first-page":"57067","DOI":"10.1021\/acsomega.5c04680","article-title":"Integrating Magnetic Bead-Based SELEX with In Silico Binding Analyses for the Identification of High-Affinity DNA Aptamers Targeting TAGLN2","volume":"10","author":"Martin","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.biopha.2026.119299_bib36","doi-asserted-by":"crossref","DOI":"10.3791\/64247","article-title":"Determining the Thermodynamic and Kinetic Association of a DNA Aptamer and Tetracycline Using Isothermal Titration Calorimetry","author":"Thoa","year":"2022","journal-title":"J. Vis. Exp."},{"key":"10.1016\/j.biopha.2026.119299_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2025.128713","article-title":"A novel G-quadruplex aptamer with high affinity for the specific detection of equine herpesvirus type 1: Comprehensive biophysical and analytical characterization","volume":"297","author":"Davoudi","year":"2026","journal-title":"Talanta"},{"key":"10.1016\/j.biopha.2026.119299_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2025.115844","article-title":"Recent advancements in aptamers as promising nanotool for therapeutic and diagnostic applications","volume":"702","author":"Alsaidan","year":"2025","journal-title":"Anal. Biochem"},{"key":"10.1016\/j.biopha.2026.119299_bib39","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s11010-022-04614-x","article-title":"Development and classification of RNA aptamers for therapeutic purposes: an updated review with emphasis on cancer","volume":"478","author":"Razlansari","year":"2023","journal-title":"Mol. Cell Biochem"},{"key":"10.1016\/j.biopha.2026.119299_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1048148","article-title":"Strategies for developing long-lasting therapeutic nucleic acid aptamer targeting circulating protein: The present and the future","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Cell Dev. Biol."},{"key":"10.1016\/j.biopha.2026.119299_bib41","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10030080","article-title":"Aptamer Therapeutics in Cancer: Current and Future","volume":"10","author":"Morita","year":"2018","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.biopha.2026.119299_bib42","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.biopha.2026.119299_bib43","doi-asserted-by":"crossref","first-page":"26369","DOI":"10.1074\/jbc.274.37.26369","article-title":"Antiproliferative activity of G-rich oligonucleotides correlates with protein binding","volume":"274","author":"Bates","year":"1999","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2026.119299_bib44","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/nchembio860","article-title":"Activating gene expression in mammalian cells with promoter-targeted duplex RNAs","volume":"3","author":"Janowski","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119299_bib45","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.omtn.2019.08.017","article-title":"Targeted Delivery of C\/EBP\u03b1-saRNA by RNA Aptamers Shows Anti-tumor Effects in a Mouse Model of Advanced PDAC","volume":"18","author":"Yoon","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119299_bib46","doi-asserted-by":"crossref","first-page":"22893","DOI":"10.18632\/oncotarget.8290","article-title":"Enhancing DPYSL3 gene expression via a promoter-targeted small activating RNA approach suppresses cancer cell motility and metastasis","volume":"7","author":"Li","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119299_bib47","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2174\/1574888X11666160607211436","article-title":"Cancer Stem Cells - Are Surface Markers Alone Sufficient?","volume":"12","author":"Nagare","year":"2017","journal-title":"Curr. Stem Cell Res Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib48","doi-asserted-by":"crossref","first-page":"32532","DOI":"10.18632\/oncotarget.8687","article-title":"Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia","volume":"7","author":"Vey","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119299_bib49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11523-017-0543-0","article-title":"Phase IB Trial of the Anti-Cancer Stem Cell DLL4-Binding Agent Demcizumab with Pemetrexed and Carboplatin as First-Line Treatment of Metastatic Non-Squamous NSCLC","volume":"13","author":"McKeage","year":"2018","journal-title":"Target Oncol."},{"key":"10.1016\/j.biopha.2026.119299_bib50","article-title":"Hedgehog Pathway Inhibitors as Targeted Cancer Therapy and Strategies to Overcome Drug Resistance","volume":"23","author":"Nguyen","year":"2022","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2026.119299_bib51","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41416-021-01389-8","article-title":"Phase 1 study of single-agent WNT974, a first-in-class Porcupine inhibitor, in patients with advanced solid tumours","volume":"125","author":"Rodon","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.biopha.2026.119299_bib52","article-title":"Unveiling the impact of CD133 on cell cycle regulation in radio- and chemo-resistance of cancer stem cells","volume":"13","author":"Wu","year":"2025","journal-title":"Front Public Health"},{"key":"10.1016\/j.biopha.2026.119299_bib53","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1039\/D1TB02729H","article-title":"Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer","volume":"10","author":"Li","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2026.119299_bib54","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40164-022-00352-4","article-title":"Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside","volume":"11","author":"Liu","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2026.119299_bib55","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.7150\/thno.17826","article-title":"Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer effectively inhibits intraperitoneal ovarian cancer growth","volume":"7","author":"Zheng","year":"2017","journal-title":"Theranostics"},{"key":"10.1016\/j.biopha.2026.119299_bib56","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.canlet.2020.12.022","article-title":"An aptamer-based drug delivery agent (CD133-apt-Dox) selectively and effectively kills liver cancer stem-like cells","volume":"501","author":"Zhou","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2026.119299_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.bpc.2024.107259","article-title":"Unveiling the characteristics of D4 and R4 aptamers for their future use in prostate cancer clinical practice","volume":"311","author":"Campos-Fern\u00e1ndez","year":"2024","journal-title":"Biophys. Chem."},{"key":"10.1016\/j.biopha.2026.119299_bib58","doi-asserted-by":"crossref","first-page":"18164","DOI":"10.1021\/acsnano.4c16628","article-title":"Multivalent Aptamer Assembly Enhances Tumor-Specific Degradation of Transforming Growth Factor-Beta to Remodel the Stromal and Immunosuppressive Cancer Microenvironment","volume":"19","author":"Liu","year":"2025","journal-title":"ACS Nano"},{"key":"10.1016\/j.biopha.2026.119299_bib59","first-page":"7483","article-title":"Multivalent RNA aptamers that inhibit CTLA-4 and enhance tumor immunity","volume":"63","author":"Santulli-Marotto","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.biopha.2026.119299_bib60","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.chembiol.2023.10.010","article-title":"Anti-tumor effect of PD-L1-targeting antagonistic aptamer-ASO delivery system with dual inhibitory function in immunotherapy","volume":"30","author":"Luo","year":"2023","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119299_bib61","doi-asserted-by":"crossref","first-page":"10878","DOI":"10.1021\/acs.jmedchem.3c00551","article-title":"Aptamers Targeting the PD-1\/PD-L1 Axis: A Perspective","volume":"66","author":"Bertrand","year":"2023","journal-title":"J. Med Chem."},{"key":"10.1016\/j.biopha.2026.119299_bib62","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1515\/mr-2022-0033","article-title":"Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives","volume":"2","author":"Liu","year":"2022","journal-title":"Med Rev. (2021)"},{"key":"10.1016\/j.biopha.2026.119299_bib63","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12032-023-02267-4","article-title":"Immune checkpoint inhibitors and cancer immunotherapy by aptamers: an overview","volume":"41","author":"Kejamurthy","year":"2023","journal-title":"Med Oncol."},{"key":"10.1016\/j.biopha.2026.119299_bib64","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41420-024-01845-3","article-title":"Antibody and antibody fragments site-specific conjugation using new Q-tag substrate of bacterial transglutaminase","volume":"10","author":"El Alaoui","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.biopha.2026.119299_bib65","doi-asserted-by":"crossref","first-page":"126","DOI":"10.2165\/00003088-199528020-00004","article-title":"Problems of delivery of monoclonal antibodies. Pharmaceutical and pharmacokinetic solutions","volume":"28","author":"Reilly","year":"1995","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.biopha.2026.119299_bib66","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.175257","article-title":"Combination of locoregional radiotherapy with a TIM-3 aptamer improves survival in diffuse midline glioma models","volume":"9","author":"Ausejo-Mauleon","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.biopha.2026.119299_bib67","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.ymthe.2017.06.023","article-title":"A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice","volume":"25","author":"Gefen","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib68","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185169","article-title":"Identification of LAG3 high affinity aptamers by HT-SELEX and Conserved Motif Accumulation (CMA)","volume":"12","author":"Soldevilla","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2026.119299_bib69","article-title":"A novel bispecific aptamer targeting LAG3 and HER2 enhances T cell-mediated immunotherapy against HER2-positive cancer cells","volume":"16","author":"Guo","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2026.119299_bib70","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1038\/mt.2012.18","article-title":"Isolation and optimization of murine IL-10 receptor blocking oligonucleotide aptamers using high-throughput sequencing","volume":"20","author":"Berezhnoy","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib71","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1038\/mt.2013.178","article-title":"A novel C5a-neutralizing mirror-image (l-)aptamer prevents organ failure and improves survival in experimental sepsis","volume":"21","author":"Hoehlig","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib72","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1038\/ncomms7481","article-title":"Structural basis for the targeting of complement anaphylatoxin C5a using a mixed L-RNA\/L-DNA aptamer","volume":"6","author":"Yatime","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119299_bib73","doi-asserted-by":"crossref","first-page":"6897","DOI":"10.1167\/iovs.12-10198","article-title":"A novel aptamer targeting TGF-beta receptor II inhibits transdifferentiation of human tenon's fibroblasts into myofibroblast","volume":"53","author":"Zhu","year":"2012","journal-title":"Invest Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.biopha.2026.119299_bib74","doi-asserted-by":"crossref","first-page":"8837","DOI":"10.18632\/aging.102997","article-title":"The TbetaR II-targeted aptamer S58 prevents fibrosis after glaucoma filtration surgery","volume":"12","author":"Li","year":"2020","journal-title":"Aging (Albany NY)"},{"key":"10.1016\/j.biopha.2026.119299_bib75","article-title":"Bispecific Nanobody-Aptamer Conjugates for Enhanced Cancer Therapy in Solid Tumors","volume":"20","author":"Wang","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.biopha.2026.119299_bib76","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijrobp.2016.05.013","article-title":"4-1BB Aptamer-Based Immunomodulation Enhances the Therapeutic Index of Radiation Therapy in Murine Tumor Models","volume":"96","author":"Benaduce","year":"2016","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.biopha.2026.119299_bib77","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/nat.2012.0388","article-title":"Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40","volume":"23","author":"Pratico","year":"2013","journal-title":"Nucleic Acid. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib78","doi-asserted-by":"crossref","DOI":"10.1038\/mtna.2013.26","article-title":"CD28 aptamers as powerful immune response modulators","volume":"2","author":"Pastor","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119299_bib79","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-79420-w","article-title":"DNA aptamer-based rolling circle amplification product as a novel immunological adjuvant","volume":"10","author":"Al-Ogaili","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.biopha.2026.119299_bib80","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1186\/s12967-023-04217-0","article-title":"RNA aptamers with specific binding affinity to CD40 (CD40Apt) represents a promising antagonist of the CD40-CD40L signaling for thyroid-associated ophthalmopathy (TAO) treatment in mouse","volume":"21","author":"Chen","year":"2023","journal-title":"J. Transl. Med"},{"key":"10.1016\/j.biopha.2026.119299_bib81","doi-asserted-by":"crossref","first-page":"23182","DOI":"10.18632\/oncotarget.8095","article-title":"MRP1-CD28 bi-specific oligonucleotide aptamers: target costimulation to drug-resistant melanoma cancer stem cells","volume":"7","author":"Soldevilla","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2026.119299_bib82","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1016\/j.chembiol.2024.03.011","article-title":"Repurposing AS1411 for constructing ANM-PROTACs","volume":"31","author":"Fu","year":"2024","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.biopha.2026.119299_bib83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s43556-025-00392-2","article-title":"Targeting tumor-infiltrating regulatory T cells: combining CD47 and PD-L1 inhibition via a novel aptamer-siRNA chimera","volume":"6","author":"Zeng","year":"2025","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.biopha.2026.119299_bib84","article-title":"Targeted siRNA delivery using aptamer-siRNA chimeras and aptamer-conjugated nanoparticles","volume":"11","author":"Sivakumar","year":"2019","journal-title":"Wiley Inter. Rev. Nanomed. Nanobiotechnol"},{"key":"10.1016\/j.biopha.2026.119299_bib85","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.omtn.2022.07.017","article-title":"A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression","volume":"29","author":"Meraviglia-Crivelli","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119299_bib86","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/1061186X.2024.2373306","article-title":"Aptamers: ushering in new hopes in targeted glioblastoma therapy","volume":"32","author":"Chatterjee","year":"2024","journal-title":"J. Drug Target"},{"key":"10.1016\/j.biopha.2026.119299_bib87","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1021\/acs.bioconjchem.5b00291","article-title":"Aptamer-Drug Conjugates","volume":"26","author":"Zhu","year":"2015","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2026.119299_bib88","doi-asserted-by":"crossref","first-page":"11838","DOI":"10.1073\/pnas.0602615103","article-title":"Aptamers evolved from live cells as effective molecular probes for cancer study","volume":"103","author":"Shangguan","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.biopha.2026.119299_bib89","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/nbt1223","article-title":"Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras","volume":"24","author":"McNamara","year":"2006","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.biopha.2026.119299_bib90","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.biopha.2016.09.035","article-title":"Cancer nanotheranostics: Strategies, promises and impediments","volume":"84","author":"Roy Chowdhury","year":"2016","journal-title":"Biomed. Pharm."},{"key":"10.1016\/j.biopha.2026.119299_bib91","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1021\/bc5004313","article-title":"Functionalizing Liposomes with anti-CD44 Aptamer for Selective Targeting of Cancer Cells","volume":"26","author":"Alshaer","year":"2015","journal-title":"Bioconjug Chem."},{"key":"10.1016\/j.biopha.2026.119299_bib92","doi-asserted-by":"crossref","DOI":"10.1016\/j.talanta.2020.121209","article-title":"Dendrimer grafted persistent luminescent nanoplatform for aptamer guided tumor imaging and acid-responsive drug delivery","volume":"219","author":"Zhang","year":"2020","journal-title":"Talanta"},{"key":"10.1016\/j.biopha.2026.119299_bib93","doi-asserted-by":"crossref","DOI":"10.1002\/smll.202306760","article-title":"Bioorthogonal Aptamer-ATTEC Conjugates for Degradation of Alpha-Synuclein via Autophagy-Lysosomal Pathway","volume":"20","author":"Liao","year":"2024","journal-title":"Small"},{"key":"10.1016\/j.biopha.2026.119299_bib94","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1038\/s41467-024-48416-9","article-title":"L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I\/II GLORIA trial","volume":"15","author":"Giordano","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.biopha.2026.119299_bib95","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.3324\/haematol.2018.205930","article-title":"Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed\/refractory chronic lymphocytic leukemia","volume":"104","author":"Steurer","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.biopha.2026.119299_bib96","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1093\/nass\/nrn031","article-title":"Physicochemical stability of NOX-E36, a 40mer L-RNA (Spiegelmer) for therapeutic applications","author":"Maasch","year":"2008","journal-title":"Nucleic Acids Symp. Ser. (Oxf."},{"key":"10.1016\/j.biopha.2026.119299_bib97","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12951-022-01240-z","article-title":"Progress in cancer drug delivery based on AS1411 oriented nanomaterials","volume":"20","author":"Tong","year":"2022","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.biopha.2026.119299_bib98","first-page":"107","article-title":"AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia","volume":"12","author":"Mongelard","year":"2010","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib99","article-title":"A dual-enzyme-like nanozyme adjuvant alleviates tumor hypoxia to enhance photothermally ferroptosis-immune synergistic tumor therapy","volume":"35","author":"Chang","year":"2025","journal-title":"Mater. Today Bio"},{"key":"10.1016\/j.biopha.2026.119299_bib100","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1007\/s10637-013-0045-6","article-title":"A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma","volume":"32","author":"Rosenberg","year":"2014","journal-title":"Invest N. Drugs"},{"key":"10.1016\/j.biopha.2026.119299_bib101","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.bbagen.2016.12.015","article-title":"G-quadruplex oligonucleotide AS1411 as a cancer-targeting agent: Uses and mechanisms","volume":"1861","author":"Bates","year":"2017","journal-title":"Biochim Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.biopha.2026.119299_bib102","article-title":"The First-in-Human Whole-Body Dynamic Pharmacokinetics Study of Aptamer","volume":"6","author":"Ding","year":"2023","journal-title":"Res. (Wash. D. C. )"},{"key":"10.1016\/j.biopha.2026.119299_bib103","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/14712598.2024.2399148","article-title":"The future of aptamers in cancer diagnosis, prognosis and treatment","volume":"24","author":"Ar\u00e9valo","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib104","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.yrtph.2013.03.001","article-title":"Pharmaceutical toxicology: designing studies to reduce animal use, while maximizing human translation","volume":"66","author":"Chapman","year":"2013","journal-title":"Regul. Toxicol. Pharm."},{"key":"10.1016\/j.biopha.2026.119299_bib105","doi-asserted-by":"crossref","first-page":"227","DOI":"10.14573\/altex.2013.2.227","article-title":"Reprint: Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice","volume":"30","author":"Leist","year":"2013","journal-title":"Altex"},{"key":"10.1016\/j.biopha.2026.119299_bib106","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omtn.2020.05.025","article-title":"Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge?","volume":"21","author":"Sola","year":"2020","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119299_bib107","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2144\/000114473","article-title":"Morph-X-Select: Morphology-based tissue aptamer selection for ovarian cancer biomarker discovery","volume":"61","author":"Wang","year":"2016","journal-title":"Biotechniques"},{"key":"10.1016\/j.biopha.2026.119299_bib108","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.biomaterials.2015.07.020","article-title":"2-fluoro-RNA oligonucleotide CD40 targeted aptamers for the control of B lymphoma and bone-marrow aplasia","volume":"67","author":"Soldevilla","year":"2015","journal-title":"Biomaterials"},{"key":"10.1016\/j.biopha.2026.119299_bib109","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1038\/mt.2009.91","article-title":"The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice","volume":"17","author":"Gao","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2026.119299_bib110","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17091091","article-title":"Polymeric Nanoparticles for Targeted Lung Cancer Treatment: Review and Perspectives","volume":"17","author":"Kapoor","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.biopha.2026.119299_bib111","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s12032-024-02530-2","article-title":"Transforming cancer detection and treatment with nanoflowers","volume":"41","author":"Prajapati","year":"2024","journal-title":"Med Oncol."},{"key":"10.1016\/j.biopha.2026.119299_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102436","article-title":"DeepAptamer: Advancing high-affinity aptamer discovery with a hybrid deep learning model","volume":"36","author":"Yang","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.biopha.2026.119299_bib113","doi-asserted-by":"crossref","first-page":"4076","DOI":"10.1021\/acs.molpharmaceut.5c00343","article-title":"AIoptamer: Artificial Intelligence-Driven Aptamer Optimization Pipeline for Targeted Therapeutics in Healthcare","volume":"22","author":"Gupta","year":"2025","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119299_bib114","doi-asserted-by":"crossref","first-page":"8825","DOI":"10.1039\/D4TB00909F","article-title":"Prediction of aptamer affinity using an artificial intelligence approach","volume":"12","author":"Fallah","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2026.119299_bib115","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13122877","article-title":"Artificial Intelligence-Driven SELEX Design of Aptamer Panels for Urinary Multi-Biomarker Detection in Prostate Cancer: A Systematic and Bibliometric Review","volume":"13","author":"Slalmi","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.biopha.2026.119299_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2025.104488","article-title":"Artificial intelligence in the development of small nucleic acid therapeutics: toward smarter and safer medicines","volume":"30","author":"Delre","year":"2025","journal-title":"Drug Discov. Today"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600332X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600332X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:51:37Z","timestamp":1779245497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600332X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":116,"alternative-id":["S075333222600332X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119299","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aptamers in cancer therapy: Why has clinical translation lagged behind preclinical promise?","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119299","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119299"}}